Immunocore Holdings (IMCR) Interest & Investment Income (2021 - 2026)

Immunocore Holdings (IMCR) has reported Interest & Investment Income for 6 consecutive years, with $3.4 million the latest figure, recorded in Q1 2026.

• Quarterly Interest & Investment Income fell 18.15% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.7 million (down 27.06% YoY) and the FY2025 annual result came in at $16.5 million, down 35.69% from the prior year.
• Interest & Investment Income slipped to $3.4 million in Q1 2026 per IMCR's latest filing, from $3.9 million in the prior quarter.
• Over the last five years, Interest & Investment Income for IMCR reached as high as $8.2 million in Q1 2024 and fell as low as $148599.1 in Q2 2022.
• A 5-year average of $4.2 million and a median of $4.2 million in 2025 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2022 — Interest & Investment Income jumped 42170.33% — and 2025, when it plunged 49.36%.
• Year by year, Interest & Investment Income stood at $2.8 million in 2022, then jumped by 90.94% to $5.4 million in 2023, then retreated by 4.91% to $5.2 million in 2024, then dropped by 24.49% to $3.9 million in 2025, then slipped by 12.49% to $3.4 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $3.4 million, $3.9 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.